Mylan fails to nix Tarceva patent leaving Astellas, Roche and Pfizer clear until 2018
This article was originally published in Scrip
Executive Summary
In US patent infringement litigation surrounding the cancer drug Tarceva (erlotinib), a US district court ruled on 1 May that two patents in a suit brought against Mylan Pharmaceuticals are valid.